These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1576 related items for PubMed ID: 15384064

  • 1. Omitting axillary lymph node dissection in sentinel node negative breast cancer patients is safe: a long term follow-up analysis.
    Torrenga H, Fabry H, van der Sijp JR, van Diest PJ, Pijpers R, Meijer S.
    J Surg Oncol; 2004 Oct 01; 88(1):4-7; discussion 7-8. PubMed ID: 15384064
    [Abstract] [Full Text] [Related]

  • 2. Erratum to: Axillary recurrence rate following negative sentinel node biopsy for invasive breast cancer: long-term follow-up.
    Kiluk JV, Ly QP, Santillan AA, Meade T, Ramos D, Reintgen DS, Dessureault S, Davis M, Shamehdi C, Cox CE.
    Ann Surg Oncol; 2010 Feb 01; 17(2):552-7. PubMed ID: 19957043
    [Abstract] [Full Text] [Related]

  • 3. Axillary lymph node dissection for sentinel lymph node micrometastases may be safely omitted in early-stage breast cancer patients: long-term outcomes of a prospective study.
    Langer I, Guller U, Viehl CT, Moch H, Wight E, Harder F, Oertli D, Zuber M.
    Ann Surg Oncol; 2009 Dec 01; 16(12):3366-74. PubMed ID: 19760047
    [Abstract] [Full Text] [Related]

  • 4. Therapeutic options and results for the management of minimally invasive carcinoma of the breast: influence of axillary dissection for treatment of T1a and T1b lesions.
    White RE, Vezeridis MP, Konstadoulakis M, Cole BF, Wanebo HJ, Bland KI.
    J Am Coll Surg; 1996 Dec 01; 183(6):575-82. PubMed ID: 8957459
    [Abstract] [Full Text] [Related]

  • 5. Sentinel lymph node as a new marker for therapeutic planning in breast cancer patients.
    Gipponi M, Bassetti C, Canavese G, Catturich A, Di Somma C, Vecchio C, Nicolò G, Schenone F, Tomei D, Cafiero F.
    J Surg Oncol; 2004 Mar 01; 85(3):102-11. PubMed ID: 14991881
    [Abstract] [Full Text] [Related]

  • 6. Patients with breast cancer and negative sentinel lymph node biopsy without additional axillary lymph node dissection: a follow-up study of up to 5 years.
    Domènech A, Benitez A, Bajén MT, Pla MJ, Gil M, Martín-Comín J.
    Oncology; 2007 Mar 01; 72(1-2):27-32. PubMed ID: 17998787
    [Abstract] [Full Text] [Related]

  • 7. Sentinel node biopsy in elderly breast cancer patients.
    Gennari R, Rotmensz N, Perego E, dos Santos G, Veronesi U.
    Surg Oncol; 2004 Dec 01; 13(4):193-6. PubMed ID: 15615656
    [Abstract] [Full Text] [Related]

  • 8. Sentinel node positive breast cancer patients who do not undergo axillary dissection: are they different?
    Zakaria S, Pantvaidya G, Reynolds CA, Grant CS, Sterioff S, Donohue JH, Farley DR, Hoskin TL, Degnim AC.
    Surgery; 2008 May 01; 143(5):641-7. PubMed ID: 18436012
    [Abstract] [Full Text] [Related]

  • 9. Long-term morbidity of patients with early breast cancer after sentinel lymph node biopsy compared to axillary lymph node dissection.
    Schulze T, Mucke J, Markwardt J, Schlag PM, Bembenek A.
    J Surg Oncol; 2006 Feb 01; 93(2):109-19. PubMed ID: 16425290
    [Abstract] [Full Text] [Related]

  • 10. Prognostic implications of isolated tumor cells and micrometastases in sentinel nodes of patients with invasive breast cancer: 10-year analysis of patients enrolled in the prospective East Carolina University/Anne Arundel Medical Center Sentinel Node Multicenter Study.
    Reed J, Rosman M, Verbanac KM, Mannie A, Cheng Z, Tafra L.
    J Am Coll Surg; 2009 Mar 01; 208(3):333-40. PubMed ID: 19317993
    [Abstract] [Full Text] [Related]

  • 11. Axillary regional recurrence after sentinel lymph node biopsy for breast cancer.
    Rosing DK, Dauphine CE, Vargas MP, Gonzalez K, Burla M, Kaufmann P, Vargas HI.
    Am Surg; 2006 Oct 01; 72(10):939-42. PubMed ID: 17058740
    [Abstract] [Full Text] [Related]

  • 12. Characteristics and outcomes of sentinel node-positive breast cancer patients after total mastectomy without axillary-specific treatment.
    Milgrom S, Cody H, Tan L, Morrow M, Pesce C, Setton J, Rogers K, Arnold B, Eaton A, Catalano J, McCormick B, Powell S, Ho A.
    Ann Surg Oncol; 2012 Nov 01; 19(12):3762-70. PubMed ID: 22576064
    [Abstract] [Full Text] [Related]

  • 13. Completion axillary lymph node dissection not required for regional control in patients with breast cancer who have micrometastases in a sentinel node.
    Yegiyants S, Romero LM, Haigh PI, DiFronzo LA.
    Arch Surg; 2010 Jun 01; 145(6):564-9. PubMed ID: 20566977
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Sentinel node mapping for breast cancer: the operative experience of a breast surgeon in a rural community.
    Davit FE, Gatmaitan P, Garguilo G.
    Am Surg; 2008 May 01; 74(5):423-7. PubMed ID: 18481500
    [Abstract] [Full Text] [Related]

  • 19. Predictors of completion axillary lymph node dissection in patients with immunohistochemical metastases to the sentinel lymph node in breast cancer.
    Pugliese MS, Karam AK, Hsu M, Stempel MM, Patil SM, Ho AY, Traina TA, Van Zee KJ, Cody HS, Morrow M, Gemignani ML.
    Ann Surg Oncol; 2010 Apr 01; 17(4):1063-8. PubMed ID: 20033325
    [Abstract] [Full Text] [Related]

  • 20. Axillary recurrence in women with a negative sentinel lymph node and no axillary dissection in breast cancer.
    Palesty JA, Foster JM, Hurd TC, Watroba N, Rezaishiraz H, Edge SB.
    J Surg Oncol; 2006 Feb 01; 93(2):129-32. PubMed ID: 16425295
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 79.